ArticleScience China. Life sciences2026
The vinculin-β-catenin axis promotes bone formation and repair: an essential prerequisite for the anti-osteoporotic efficacy of sclerostin-neutralizing antibody.
Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IFT88/Kindlin-2 Signaling Prevents Mechanical Overloading-Induced PANoptosis of Nucleus Pulposus Cells by Activating FOXP1 SUMOylation.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, targeting the Wnt/β-catenin pathway to promote bone formation is a primary strategy for the development of osteoporosis drugs. Here, we demonstrate that vinculin promotes bone mass increase and fracture repair by elevating the β-catenin protein levels in mesenchymal stem cells (MSCs). Furthermore, it is revealed that vinculin is required for sclerostin-neutralizing antibody (Scl-Ab) to increase the bone mass in mice. We find that promoter accessibility and the expression of the Vcl gene, which encodes vinculin, are reduced in the MSCs from elderly human individuals, and vinculin knockdown impairs osteoblast differentiation in vitro. Genetic deletion of Vcl in Prx1-expressing cells in mice leads to pronounced bone loss in weight-bearing long bones, but not in the non-weight-bearing skull, primarily attributed to severely impaired bone formation, characterized by reduced osteoblastic and increased adipogenic differentiation. Unexpectedly, vinculin loss decreases the β-catenin protein levels by approximately 80% in MSCs in vitro and in the bone. Mechanistically, vinculin binds to β-catenin and blocks GSK-3 phosphorylation and the subsequent ubiquitin-proteasomal degradation of β-catenin, thereby stabilizing β-catenin. Thus, mutating the β-catenin GSK-3 phosphorylation sites abolishes the ability of vinculin deficiency to destabilize β-catenin, and the pharmacological inhibition of GSK-3 activity restores the bone loss induced by vinculin ablation in mice. Furthermore, deleting vinculin expression in chondrocytes impairs bone fracture healing, while a hydrogel containing MSCs overexpressing vinculin in mice promotes fracture healing. Importantly, vinculin loss abolishes the ability of sclerostin-neutralizing antibody Scl-Ab, a current primary anti-osteoporotic treatment, to increase bone mass in mice. Thus, we demonstrate that the vinculin-β-catenin axis in MSCs promotes bone formation and fracture healing and is essential for the effectiveness of current osteoporosis drugs.
Indexed as
Identifiers
41569384What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.